Response
Group . | N . | CR, no. of patients . | CRp, no. of patients . | OR, no. of patients (%) . | Median no. of courses to response (range) . | Median response duration, mo (range) . |
|---|---|---|---|---|---|---|
| VPA dose | ||||||
| 20 mg/kg | 3 | 1 | 0 | 1 (33) | 2 | 9 |
| 35 mg/kg | 9 | 1 | 0 | 1 (11) | 3 | 5.4 |
| 50 mg/kg | 41 | 8 | 2 | 10 (23) | 1 (1-3) | 4.5 (2-10.4+) |
| Total | 53 | 10 | 2 | 12 (22) | 1 (1-3) | 5.6 (2-10.4+) |
| Previously untreated | 10 | 4 | 1 | 5 (50) | 1 (1-3) | 3.3 (2-6.3+) |
Group . | N . | CR, no. of patients . | CRp, no. of patients . | OR, no. of patients (%) . | Median no. of courses to response (range) . | Median response duration, mo (range) . |
|---|---|---|---|---|---|---|
| VPA dose | ||||||
| 20 mg/kg | 3 | 1 | 0 | 1 (33) | 2 | 9 |
| 35 mg/kg | 9 | 1 | 0 | 1 (11) | 3 | 5.4 |
| 50 mg/kg | 41 | 8 | 2 | 10 (23) | 1 (1-3) | 4.5 (2-10.4+) |
| Total | 53 | 10 | 2 | 12 (22) | 1 (1-3) | 5.6 (2-10.4+) |
| Previously untreated | 10 | 4 | 1 | 5 (50) | 1 (1-3) | 3.3 (2-6.3+) |